Surmodicsâ„¢ IVD Revenue and Competitors
Estimated Revenue & Valuation
- Surmodicsâ„¢ IVD's estimated annual revenue is currently $2.6M per year.
- Surmodicsâ„¢ IVD's estimated revenue per employee is $155,000
Employee Data
- Surmodicsâ„¢ IVD has 17 Employees.
- Surmodicsâ„¢ IVD grew their employee count by 21% last year.
Surmodicsâ„¢ IVD's People
Name | Title | Email/Phone |
---|---|---|
1 | Scientific Review Officer | Reveal Email/Phone |
Surmodicsâ„¢ IVD Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 49 | 20% | N/A | N/A |
#2 | $7.4M | 48 | -35% | N/A | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $0.3M | 2 | -91% | N/A | N/A |
#5 | $3.6M | 23 | 5% | N/A | N/A |
#6 | $0.9M | 7 | 40% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $14.7M | 84 | 8% | N/A | N/A |
#9 | $14.7M | 95 | 0% | $20.5M | N/A |
#10 | $27.9M | 144 | 13% | $39.1M | N/A |
What Is Surmodicsâ„¢ IVD?
At Surmodics™ IVD, we provide assay developers a comprehensive toolkit for immunoassay development. Whether you are developing an ELISA/EIA, immunoblot/western blot, line assay or microarray, our IVD products are differentiated with high-performance formulations that provide a quicker path to commercialization. Our product portfolio consists of the industry’s gold standard protein stabilizers, diluents and blockers, best-in-class substrates and stop solutions, DIARECT™ antigens and antibodies as well as a variety of surface coatings for molecular diagnostic and immunoassay applications. Surmodics is your partner in Quality. Visit our website to learn more about our ISO 13485:2016 & ISO 9001:2015 certifications and IVD technology.
keywords:N/AN/A
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 19 | -30% | N/A |
#2 | $0.4M | 19 | 171% | N/A |
#3 | $7.5M | 20 | 33% | N/A |
#4 | $2M | 20 | 0% | N/A |
#5 | $3.7M | 20 | 11% | N/A |